Crossmark

Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone

Crossref DOI link: https://doi.org/10.1007/s00262-019-02377-x

Published Online: 2019-08-17

Published Print: 2019-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rafei-Shamsabadi, David https://orcid.org/0000-0002-7850-3199
Lehr, Saskia

von Bubnoff, Dagmar

Meiss, Frank https://orcid.org/0000-0002-4044-9094
Funding

Funding for this research was provided by:

Else Kröner-Fresenius-Stiftung
License Information

Text and Data Mining valid from 2019-08-17

Version of Record valid from 2019-08-17
More Information

Article History

Received: 22 April 2019

Accepted: 9 August 2019

First Online: 17 August 2019

Compliance with ethical standards

:

: Frank Meiss received honoraria for talks from BMS (Bristol-Myers Squibb), Novartis, Pierre Fabre and was participating in advisory boards of BMS, Novartis, Pierre Fabre and Roche. All other authors declare that they have no conflict of interest.

: This study was approved by the local ethics committee of the University of Freiburg (approval vote: 478/18). Guidelines from the Declaration of Helsinki of 1975 were followed.

: All patients received detailed information about risks, benefits and possible side effects of combination therapy with PD-1 inhibitor and interleukin-2. All patients gave written informed consent to this individual treatment decision. Furthermore, all patients gave written informed consent to the use of their tumor specimens and clinical data for research and publication. This included the use of immunohistochemical staining of tumor biopsies, radiologic (CT and PET–CT scans), ultrasound as well as clinical images.

Document is current

Any future updates will be listed below